Crestline Management, LP United Therapeutics Corp Transaction History

Crestline Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$205.95 - $280.43 $25,743 - $35,053	125 Added 1.03%	12,306 $3.42 Million
Q3 2022 Nov 14, 2022	BUY	$203.3 - $244.17 $1.04 Million - $1.25 Million	5,123 Added 72.58%	12,181 $2.55 Million
Q2 2022 Aug 12, 2022	SELL	$174.81 - $241.14 $279,870 - $386,065	-1,601 Reduced 18.49%	7,058 $1.66 Million
Q1 2022 May 16, 2022	SELL	$166.16 - $213.96 $1.93 Million - $2.48 Million	-11,597 Reduced 57.25%	8,659 $1.55 Million
Q4 2021 Feb 14, 2022	BUY	$184.32 - $216.08 $555,540 - $651,265	3,014 Added 17.48%	20,256 $4.38 Million
Q3 2021 Nov 12, 2021	BUY	$179.86 - $214.88 $1.08 Million - $1.29 Million	5,987 Added 53.19%	17,242 $3.18 Million
Q2 2021 Aug 13, 2021	BUY	$170.47 - $211.93 $1.92 Million - $2.39 Million	11,255 New	11,255 $2.02 Million
Q4 2019 Feb 12, 2020	SELL	$78.31 - $95.34 $2.94 Million - $3.58 Million	-37,500 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$74.85 - $85.99 $1.83 Million - $2.11 Million	24,500 Added 188.46%	37,500 $2.99 Million
Q2 2019 Aug 13, 2019	BUY	$76.06 - $120.81 $988,780 - $1.57 Million	13,000 New	13,000 $1.02 Million

672

42.4M

194K

295K

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.5B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

Get notified when there are updates to the investment portfolio of Crestline Management, LP, based on Form 13F filings with the SEC.

Stay updated on Crestline Management, LP with notifications on news.